ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1414

Investigation of the Association Between Gastroesophageal Reflux Disease and Clinical Factors in Patients with Rheumatoid Arthritis

Katsushi Ishii1, Yuichi Mochida1, Yuki Ozawa1, Naoto Mitsugi2 and Tomoyuki Saito3, 1Center for Rheumatic Diseases, Yokohama City University Medical Center, Yokohama, Japan, 2Orthopaedic Surgery, Yokohama City University Medical Center, Yokohama, Japan, 3Orthopaedic Surgery, Yokohama City University School of Medicine, Yokohama, Japan

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Gastrointestinal complications and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects (ACR): Comorbidities, Treatment Outcomes and Mortality

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Gastroesophageal reflux disease (GERD) is caused by the abnormal reflux of the gastric contents into the esophagus. Many risk factors are considered as a cause of GERD. Nonsteroidal anti-inflammatory drugs (NSAIDs) consumption is regard as one cause of the development of GERD; but, there are few reports regarding the relationship between NSAIDs consumption and the development of GERD. NSAIDs are commonly used to control pain, inflammation related to patients with rheumatoid arthritis (RA). Therefore, the prevalence of GERD in RA may be high because of high rate of NSAIDs consumption. However, there are few reports regarding as the development of GERD in RA. The purpose of this study was to examine the prevalence of GERD in RA. We also investigate the association between GERD and clinical factors in RA.

Methods: We investigated 378 outpatients with RA (70 males, 308 females). Three rheumatologist of orthopaedic surgery examined all patients. The presence or absence of GERD was evaluated by using GerdQ questionnaire. It is well known that GerdQ can be used to diagnose GERD with an accuracy similar to that of the gastroenterologist. When heartburn or acid regurgitation symptoms are observed more than once a week, the patients are diagnosed with GERD. The correlation between GERD and clinical factors such as age, sex, height, weight, BMI, disease duration, DAS28/DAS28-CRP/SDAI, Pt-VAS, and medication drugs (NSAIDs, steroid, bisphosphonate, and gatroprotective agents) were analyzed.

Results: The GERD symptoms were observed in 96 of these 378 patients (25.4%). SDAI and patient’s VAS were significantly higher in the GERD positive group than in the GERD negative group (p<0.05). DAS28 and DAS28-CRP were higher in the GERD positive group than in the GERD negative group, but these differences did not reach statistical significances. There was no statistical correlation between the presence or absence of GERD symptoms and the presence or absence of taking NSAIDs, steroid, and bisphosphonate.

Conclusion: The prevalence of GERD in RA (25.4%) was higher than that in the Japanese healthy population (7.6-10.6%). The prevalence of GERD in RA was high and associated with Pt-VAS. Therefore, we should pay attention to the complication of GERD when the evaluation of disease activity of RA.


Disclosure:

K. Ishii,
None;

Y. Mochida,
None;

Y. Ozawa,
None;

N. Mitsugi,
None;

T. Saito,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/investigation-of-the-association-between-gastroesophageal-reflux-disease-and-clinical-factors-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology